Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Super-Affinity Antibody

Anti-RAD51 Antibody (R1A40)

Catalog #:   RHG09801 Specific References (50) DATASHEET
Host species: Rabbit
Isotype: IgG
Applications: FCM, IF, IHC, IP, WB
Accession: Q06609
Overview

Catalog No.

RHG09801

Species reactivity

Human, Mouse, Rat

Host species

Rabbit

Isotype

IgG

Clonality

Monoclonal

Tested applications

FCM: 1:20-1:100, IF: 1:50-1:200, IHC: 1:100-1:200, IP: 1:20-1:50, WB: 1:1000-1:5000

Target

RAD51 homolog A, DNA repair protein RAD51 homolog 1, RAD51A, RECAhomolog S. cerevisiae, RAD51A, RECA, Rad 51, RecA homolog E. coli, RecA like protein, RAD51

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q06609

Applications

FCM, IF, IHC, IP, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% BSA, 50% Glycerol, 0.05% Sodium azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at +4 ℃ short term (1-2 weeks). Store at -20 ℃ 12 months. Store at -80 ℃ long term.

Clone ID

R1A40

Data Image
  • Immunohistochemical
    Immunohistochemical analysis of paraffin-embedded mouse kidney, using Rad51 Antibody.
  • Western blot
    All lanes use the Antibody at 1:3K dilution for 1 hour at room temperature.
  • Western blot
    All lanes use the Antibody at 1:5K dilution for 1 hour at room temperature.
  • Western blot
    Western blot analysis of Rad51 in (1)HEK293 cell lysate; (2)K562 cell lysate.
References

Mass cytometric detection of homologous recombination proficiency in circulating tumor cells to predict chemoresistance of metastatic breast cancer patients., PMID:40456663

The influence of homologous recombination repair on temozolomide chemosensitivity in gliomas., PMID:40120126

Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional immunofluorescence., PMID:39914385

Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition., PMID:39352803

Atrial fibrillation recurrence after catheter ablation is associated with RAD51 and p63 proteins., PMID:38988509

KIN17 functions in DNA damage repair and chemosensitivity by modulating RAD51 in hepatocellular carcinoma., PMID:38935235

Meiotic protein SYCP2 confers resistance to DNA-damaging agents through R-loop-mediated DNA repair., PMID:38383600

Photonic Crystal Surface Mode Real-Time Imaging of RAD51 DNA Repair Protein Interaction with the ssDNA Substrate., PMID:38248420

Studying the DNA damage response pathway in hematopoietic canine cancer cell lines, a necessary step for finding targets to generate new therapies to treat cancer in dogs., PMID:37655260

Identification of RAD51 foci in cancer-associated circulating cells of patients with high-grade serous ovarian cancer: association with treatment outcomes., PMID:37541687

Inhibition of p53 and ATRX increases telomeric recombination in primary fibroblasts., PMID:37499040

Three-color dSTORM Imaging and Analysis of Recombination Foci in Mouse Spread Meiotic Nuclei., PMID:37497444

Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis., PMID:36564284

Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial., PMID:36156447

Dynamics of DNA damage response markers, RAD51 and XRCC1, throughout the menstrual cycle and pregnancy in healthy women. Increment during pregnancy and relation to a low titer of antinuclear antibodies., PMID:35816185

Multiplexed-Based Assessment of DNA Damage Response to Chemotherapies Using Cell Imaging Cytometry., PMID:35628514

The RNA-binding protein La/SSB associates with radiation-induced DNA double-strand breaks in lung cancer cell lines., PMID:34636174

Gefitinib Combined with Cetuximab for the Treatment of Lung Adenocarcinoma Harboring the EGFR-Intergenic Region (SEC61G) Fusion and EGFR Amplification., PMID:34342091

Reproductive Isolation Between Taxonomically Controversial Forms of the Gray Voles (Microtus, Rodentia; Arvicolinae): Cytological Mechanisms and Taxonomical Implications., PMID:34040633

In search for biomarkers and potential drug targets for uterine serous endometrial cancer., PMID:33754208

Kinase CDK2 in Mammalian Meiotic Prophase I: Screening for Hetero- and Homomorphic Sex Chromosomes., PMID:33671248

Impact of hypoxia on the double-strand break repair after photon and carbon ion irradiation of radioresistant HNSCC cells., PMID:33288855

Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer., PMID:33196706

Detection of DSBs in C. elegans Meiosis., PMID:32840787

Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment., PMID:32778095

Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma., PMID:32653671

CDK5 Activates Hippo Signaling to Confer Resistance to Radiation Therapy Via Upregulating TAZ in Lung Cancer., PMID:32407930

[Hereditary breast carcinomas pathologist's perspective]., PMID:32241645

Abnormal expression of p-ATM/CHK2 in nasal extranodal NK/T cell lymphoma, nasal type, is correlated with poor prognosis., PMID:32220941

A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma., PMID:32060401

Chemotherapy combined with bevacizumab for the treatment of advanced lung adenocarcinoma cancer harboring EGFR-ANXA2, EGFR-RAD51, ATR and BRCA2 mutations: A case report., PMID:31865638

A Novel Cell-Penetrating Antibody Fragment Inhibits the DNA Repair Protein RAD51., PMID:31375703

Biallelic germline BRCA1 mutations in a patient with early onset breast cancer, mild Fanconi anemia-like phenotype, and no chromosome fragility., PMID:31347298

Synthetic lethality of a cell-penetrating anti-RAD51 antibody in PTEN-deficient melanoma and glioma cells., PMID:30863489

Analysis of S100A11 in DNA Damage Repair., PMID:30710290

FKBP25 participates in DNA double-strand break repair., PMID:30620620

ATR-Mediated Global Fork Slowing and Reversal Assist Fork Traverse and Prevent Chromosomal Breakage at DNA Interstrand Cross-Links., PMID:30184498

A cell-penetrating antibody inhibits human RAD51 via direct binding., PMID:29036688

Silver nanoparticles coupled to anti‑EGFR antibodies sensitize nasopharyngeal carcinoma cells to irradiation., PMID:28990103

Meiotic Recombination in the Giraffe (G. reticulata)., PMID:28723680

Genetic and Small Molecule Disruption of the AID/RAD51 Axis Similarly Protects Nonobese Diabetic Mice from Type 1 Diabetes through Expansion of Regulatory B Lymphocytes., PMID:28461573

Chromatin organization revealed by nanostructure of irradiation induced γH2AX, 53BP1 and Rad51 foci., PMID:28094292

Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial., PMID:27884140

Accession of Tumor Heterogeneity by Multiplex Transcriptome Profiling of Single Circulating Tumor Cells., PMID:27630154

MAR-Mediated transgene integration into permissive chromatin and increased expression by recombination pathway engineering., PMID:27575535

Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib., PMID:27702817

Mapping Recombination Initiation Sites Using Chromatin Immunoprecipitation., PMID:27511175

Cell Killing Mechanisms and Impact on Gene Expression by Gemcitabine and 212Pb-Trastuzumab Treatment in a Disseminated i.p. Tumor Model., PMID:27467592

RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance., PMID:27454289

Mechanisms of Cell Killing Response from Low Linear Energy Transfer (LET) Radiation Originating from (177)Lu Radioimmunotherapy Targeting Disseminated Intraperitoneal Tumor Xenografts., PMID:27196891

Datasheet

Document Download

Anti-RAD51 Antibody (R1A40).pdf

 

$ 290
Product specifications
50 μg 290 100 μg 484

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-RAD51 Antibody (R1A40) [RHG09801]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only